Here’s a nifty chart:

Not exactly sure what you call that formation, but MIV Therapeutics has definitely been on a tear. I suggested some partial sales lower down–for which I make no apologies– meant great returns if you sold a bit. The shares hit $1.75–mommy– this am and now seem to be pulling back a snick.

The shares show little weakness here, but will likely pull back some more before trying to breach the $1.75 again. If you have cheap stock, hold some. Buyers here might want to leg in should the shares back up some more. Volatile, but a great trader.

Oil is the word..even if there isn’t any yet

Eden has been range bound between $6-$7 for a while. Don’t really care since we alerted the SmallCap readership at $2.80. A run over $8 could be interesting if it materializes as there would likely be some significant short covering. I don’t have those figures, but given the volume, there is likely a bunch of shorting going on.

Again, hang on to some cheap stock and use a bit to trade the swings if you’re so inclined. Great trader as well.

Trade Safely. And a thought–and maybe a donation– for the folks in the South East…

Where to begin… as we noted in our SmallCap Digest piece Tuesday, at just over $1, MIV Therapeutics looked ripe for a partial sale to lower a cost base. The share price had tripled since our initial alert at 34 cents. Likely the rational course, but since then, the shares have gone up again. Now they’re at $1.25. The company released a PR last night detailing that it had been recipient of a prestigious award:

“….(MIVT) has been recognized by Frost & Sullivan with the 2005 Technology Innovation Award, in recognition of the Company’s achievements and pioneering work to develop proprietary biocompatible coatings technology to make better, safer vascular stents, medical devices and drug delivery systems.” Cool stuff. Full Press Release is here.

Hope you didn’t sell it all. When we say a partial sale it is for strategic reasons and to lock in some profits; not a call to completely bail out. A core MIVT position in the spec end of a portfolio appears warranted.

Our next resistance level looks to be around $1.28. If you waited to sell a bit, that level should be watched. A partial sale there or at least a sell stop to lock in profits, depending on your purchase price, would likely be the smart play.

Spectrum Rises

We had mentioned frequently that the drop in Spectrum to the $1 level appeared goofy. The Company released first half earnings earlier this week and those, along with a letter to shareholders on its website from new CEO Darryl Horne. Both seemed to have turned the shares and they rose to the mid $1.50 level as of the opening this am. Some selling and likely a bit of profit taking have subdued them to the $1.45 level at the moment. Here’s the weekly chart:

Short term traders who bought the shares for a trade could likely sell a chunk here as it has retraced .382 of the recent large selloff. I’d like to purchase it–in a perfect world– if it moved back to the $1 level. If the shares put together any strength, there is the possibility of a continued run to test the .618 level at $1.95. But this is Spectrum, so there are no guarantees as to what happens next.

The company appears to be both addressing issues, delivering results and getting it’s act together after what can only be described as a very volatile period.

Trade Safely.

We published a piece on MIV Therapeutics this am. Great company, but since the share price has spiked, a partial sale may well be in order. From the piece:

“We Alerted readers to MIV Therapeutics (OTCBB: MIVT) in March 2005 at 34 cents. Tuesday, the share price surpassed a $1—a 200 percent return in a scant 5 months. And in our opinion, there’s likely much more to come.

Technically, the chart shows a share price target of around $1.02. Investors who bought the shares significantly lower or particularly around our 34 cent alert price in March would be excused if they let a small bit go to lower a cost base. You may well get to replace sold shares should the price dip from here, which, anywhere above 96 cents, is a new 52-week high. Tuesday’s early trading saw the shares exceed that level and were changing hands at $1.04 at this writing. The retracement levels on a pullback are at 88 and 78 cents, according to the chart.”

You’re up to date. maintain a good core position in the shares. Looks like a winner long-term.

NB: Slight miscalculation corrected above… the share price has tripled, but the return is 200 percent, not 300. Got a bit excited, apparently. Still pretty darned good…

After touching $3 in late July, Biophan has pulled back nicely and is looking attractive. Here’s the chart:

This level around $2.60-$2.70 looks a good risk/reward entry point as it breaks its.382 retracement point. However, if it doesn’t rally, it could well test the .618 point just below $2.40. For the sake of a dime or 20 cents, might be worth a shot here and/or you can pick up more shares if it pulls back to $2.40.

Thought you’d like to know.

Trade safely.

I’m looking at the tech picture for three of our stocks. All are volatile, some need to be bought, some sold.

First up, Eden Energy.

We suggested on this blog taking a partial profit when the shares were over $9. Now, for those who want to replace a sold position or have been waiting for an entry, this is likely it.Or close to it. The shares are sitting on a perfect .618 retracement of its recent move. Volatility is personified by EDNE, so a stop at $4.50 would be smart.

EDNE is still in the spec category until more news comes from Noah or other developments such as the commencement of the drilling program.

Govern your trading accordingly. Not for the faint of heart.

The Bottomline

Bottomline has been a goody. Here’s the chart. We brought this to you a few months ago at $10 and change. It’s trading at $17.50-ish today.

Extremely volatile. I think we’re near a top as volume is weakening and would look in gains by selling at least a portion or more. Use the 52 week high as a guide. I would sell some now and more as or if we approach that level of $18.62. Earnings report was good and the company will likely prosper. A 70 percent return in a few months should be taken advantage of. There’ll be another opportunity on this one.

INFORMATICA

Unlike EPAY above, INFA looks constructive. We Alerted readers at $7.48 in November last and the shares are cruising through $11 today.

Here’s the chart.

Stock appears tradable. Runs are followed by decent pullbacks and consolidation. No apparent sell signals as yet, so traders can likely continue to sell the rallies and buy the dips. A profit sell stop to protect gains makes sense in this market environment. Simply a good company reacting well to a growing business.

Good Weekend. Trade Safely. Send comments.

As I said in my previous comments, when Spectrum was $1.10, I have no idea why the shares are acting so badly.

Here’s the chart:

Seems to want to stay around $1, and as said, it took out the June low. I suspect that there has been some shorting going on and it may well rally on short covering if we get some traction. Company seems on track with new contracts and decent management moves, so go figure. been some good trading opportunities on this as it ran from our initial alert at $1.80 to $4 last year. Some decent action since then for traders, but long-term holders will have to hang on longer, apparently.

As I said, a puzzlement. Any comments out there?

Smallcap Digest Alerted the readership on August 1 to Novelos Therapeutics, a compelling cancer therapy company. In addition, we published a piece Monday morning detailing the positive results of the company’s Phase 1/2 clinical study with regard to it’s proprietary compound, NOV-002 and it’s ability to improve the chemotherapy regimen for the deadly scourge of non small cell lung cancer (NSCLC).

As well, the company was the subject of an article published Saturday in BioCentury, a well read and high profile biotech magazine.

All in all the story looks both interesting and potentially very profitable for shareholders. The compounds are inexpensive to produce and courtesy of extensive testing in Russia and now results from the US Phase 1/2 clinical study, looks like they may well have the kind of safety and efficacy that can both improve chemo for diseases like NSCLC, and also make chemo resistant forms such as ovarian more susceptible to treatment.

And Novelos’s other compound, NOV-205 looks to be a viable therapy for Hepatitis B and C.

Here’s the chart.

You’ll want to keep up with this one as the progress is moving quickly and looks to be one investors will want to own. As you’ll note from our August piece, the company has a solid clinical development plan to move the compounds through Phase testing and ultimately to commercialization.

Interested in any comments or observations on this one.

Trade Safely

For those who bought Eden off of our Trading Alert on April 26th at around $2.80-$3 or around that level should let a portion go as the shares are currently trading at $9.32, or north of 200 percent return in just 3.5 months.

We can’t provide other comments other than greed is ugly and there will likely be a pullback at some point given the volatility. Once that happens we’ll do the pullback numbers, but we won’t know those until it weakens.

Could well be running on the Government’s earmarking of $3 billion in direct spending and tax breaks for drilling in high-risk areas as well as a further $1 billion in Government subsidies.

We still like the prospects for Eden, very much, but it’s always prudent to sell some into rallies, especially when a stock is as volatile as this one. Keep a core position, but lowering a cost base is always a good strategic move.

A beauty for sure. And the best is likely still to come.

Trade safely

Late addition: the shares closed Monday at $8.80 after going as high as $9.96 and as low as $6.19. Now that’s volatility. Comments above still hold. Your comments welcome.